Iptacopan Speeds Kidney Protein Reduction in Vasculitis
An interim phase 2 study found adding iptacopan to standard therapy cut urine protein earlier than placebo in active AAV patients.
Updated on Nov. 11, 2026 in Asthma

Iptacopan, an oral factor B inhibitor targeting the alternative complement pathway, was added to rituximab and a glucocorticoid taper in a randomized study of 84 participants with active ANCA-associated vasculitis (AAV). Patients receiving iptacopan showed greater urine protein reduction than those on placebo.
Why it matters
AAV can damage the kidneys and other organs, and standard treatment relies on immunosuppressive drugs with significant side effects. Early evidence that targeting the complement pathway reduces kidney protein loss could inform future treatment strategies for patients with this condition.
The phase 2 study randomized 84 participants, 40 to iptacopan and 43 to placebo, with 53 (63.9%) having baseline kidney involvement, and week 24 interim data showed UPCR reductions of 40% versus 30%. Week 48 remission outcomes and the full long-term safety profile remain unreported.
The details
Participants received 200 mg of iptacopan twice daily or placebo for 24 weeks alongside rituximab and a protocol-defined glucocorticoid taper, followed by a 24-week open-label maintenance period. Adverse event rates were similar between groups and infection rates were low, according to the interim analysis presented at ASN Kidney Week 2026 in Denver.
Timeline
October 24, 2026: Interim results presented at ASN Kidney Week 2026 in Denver.
Week 4: Early UPCR and complement biomarker reductions observed.
Week 24: Interim renal-focused analysis endpoint reached.
Week 48: Primary endpoint of sustained remission to be assessed.
Big Picture
This interim phase 2 result extends the complement-inhibition strategy now being tested in ANCA-associated vasculitis, positioning an oral factor B inhibitor as a possible alternative to infusion-based complement blockade. Whether the early biomarker effects translate into sustained remission at week 48 remains to be seen.
Patients with AAV currently rely largely on immunosuppressive regimens, and an oral complement inhibitor that works alongside standard therapy could eventually offer a different treatment option. Any change to care would depend on results from longer-term and larger studies.
The takeaway
Early biomarker and urine protein reductions are encouraging, but sustained remission data will determine whether complement-pathway inhibition meaningfully changes outcomes for people with ANCA-associated vasculitis.
What happens next
Week 48 sustained-remission results from the phase 2 study are the next anticipated data point.
Further reading
For broader context on immune-related chronic conditions, explore more in Asthma.
Source note: This article includes information reported by Renal and Urology News.



